Comparison of patients with dermatomyositis in a specialty clinic versus clinical trial with anabasum (JBT-101), a cannabinoid receptor type 2 agonist

Category Primary study
JournalArthritis and Rheumatology
Year 2017
This article has no abstract
Epistemonikos ID: 04f11d3c544c59f0c491b8153a42f7c257c65a2f
First added on: Feb 08, 2025